Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.80 |
| ▸ | CHAT | P28329 | 2/20 | 0.76 |
| ▸ | EP300 | Q09472 | 4/20 | 0.75 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 2/20 | 0.75 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.75 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510587 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL188713 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL14836951 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1331291 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19181352 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL2513740 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL188145 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL188242 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6061352 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL31338605 | 1.00 | NAA50 (0.80) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2240449-B1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | CENTRE NAT RECH SCIENT (FR) | 2016-01-06 | — | — | EP | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-8710073-B2 | Anti-infective derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2014-04-29 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110092536-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFOQUE (C.N. (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2240449-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | Centre National de la Recherche Scientifique - CNRS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20100143940-A1 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2009101345-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092536-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | DHFR, COASY, QDPR | NAA50 750/4885CHAT 3492/4885EP300 633/4885 |
| US-20100143940-A1 | (3R)-HYDROXYACYL-ACP DEHYDRATASE ENZYMES USED IN THE BIOSYNTHESIS OF MYCOLIC ACIDS AND USE OF SAME FOR SCREENING ANTIBIOTICS | COASY, RIMKLA, HAGH | NAA50 228/4885CHAT 1154/4885EP300 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.